Ad Blocker Detected
Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.
The next-generation FidoCure® DNA Sequencing Test is offered to veterinary customers serviced by IDEXX reference laboratories
PALO ALTO, California, January 13, 2022 /PRNewswire/ — One Health Company, an organic company bridging the gap between precision medicine for canine and human cancer, today announced a collaboration with IDEXX Laboratories, Inc., a global leader in pet health. IDEXX Reference Laboratories will offer the FidoCure Next Generation DNA Sequencing Test to its veterinary customers in The United States and Canada Later this month.
The collaboration, which expands IDEXX’s cancer care management portfolio, enables veterinarians to provide personalized care to their cancer patients by expanding access to FidoCure’s precision medicine platform.
Cancer treatment in dogs is a huge unmet need. About six million new canine cancer diagnoses are made each year, and approximately one in three dogs will develop cancer in their lifetime. Humans and dogs are both susceptible to genetic mutations that can cause cancer to grow and spread, and identifying these mutations through genetic sequencing allows for personalized treatment and care. Like the Human Cancer Centers of Excellence, One Health Company addresses unmet cancer needs for dogs by providing streamlined access to genetic sequencing and targeted therapy.
Over 2,000 dogs diagnosed with cancer have used the FidoCure Next Generation DNA Sequencing Test. Based on the results, eligible dogs were offered individualized treatment options using targeted therapies approved by the FDA for treating humans. This collaboration will allow FidoCure, which already has the world’s largest proprietary canine cancer dataset, to significantly expand that dataset and uncover new discoveries for the benefit of dogs and humans with cancer.
“We are excited to be collaborating with a global leader in veterinary diagnostics to help bring our novel FidoCure Next Generation DNA sequencing test to even more veterinary clinics across the United States Canada,” said Christina Lopes, Co-Founder and CEO of One Health Company. “IDEXX’s customer and innovation-centric approach to veterinary diagnostics is an ideal complement to FidoCure’s precision medicine platform.”
The story goes on
About One Health Company
One Health Company is the first to bring the latest advances in human oncology – individualized precision medicine – to dogs with cancer. We are a mission driven company providing the most sophisticated diagnostics and creating a customized treatment plan for each dog. Our flagship product, FidoCure®, leverages what has been approved for human use with additional data specific to canine cancer. With FidoCure, dogs with cancer gain access to the latest scientific advances in cancer care, from testing to treatment. FidoCure is backed by leading biotech investors including Polaris Ventures, A16Z and YCombinator. Learn more at fidocure.com.
David Cirill, firstname.lastname@example.org
View original content: https://www.prnewswire.com/news-releases/one-health-company-collaborates-with-idexx-to-expand-access-to-fidocure-precision-medicine-platform-301460700.html
SOURCE The One Health Company